MacroGenics, Inc.
NASDAQ:MGNXBiotechnology
+$0.08 today
- Market cap
- $125.90M
- Beta
- 1.20
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.11
Volume 0.72M
Average 0.98M
MGNX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
MacroGenics, Inc.NASDAQ: MGNX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $1.69M fell 4.7% year over year, ahead of the -7.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 8.6% from the prior quarter. Over 3 fiscal years it compounded at -22.5% a year.
Context
- Depreciation & amortization amounted to 3.7% of revenue in FY2025, down 1.4 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -4.7% holds above the trailing-twelve-month pace of -7.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 5.52M USD
- Year-over-year change
- -26.7%
- 4-year CAGR
- -16.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.52M | -26.7% |
| FY2024 | 2024-12-31 | 7.54M | -21.8% |
| FY2023 | 2023-12-31 | 9.65M | -18.7% |
| FY2022 | 2022-12-31 | 11.87M | +5.4% |
| FY2021 | 2021-12-31 | 11.26M | — |
Depreciation & Amortization vs competitors
How MGNX compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -7.1% is the 4th highest of 11, against a peer median of -17.6%.
- Depreciation & amortization amounts to 4.4% of revenue for MGNX, versus a peer median of 364.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.94M USD | -7.1% | -22.5% | 4.4% | |
| LTM Mar 2026 | $3.64M USD | -3.9% | +6.3% | 364.3% | |
| LTM Mar 2026 | $1.45M USD | -11.2% | +13.6% | 1079.1% | |
| FY2025 | $704K USD | +6.7% | -11.4% | 1100.0% | |
| LTM Mar 2026 | $628K USD | -48.8% | -19.7% | — | |
| LTM Mar 2026 | €377.74K EUR | -20.5% | -12.3% | 1287.9% | |
| LTM Mar 2026 | $168K USD | -72.2% | -41.8% | 2.4% | |
| LTM Mar 2026 | $121K USD | -27.5% | +27.8% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $79K USD | -59.1% | -20.8% | 1.1% |
| LTM Mar 2026 | $23.33K USD | -14.7% | +0.0% | 0.3% | |
| LTM Mar 2026 | $16.88K USD | +36.5% | +20.6% | — | |
| Peer median (excluding MGNX) | — | -17.6% | -5.7% | 364.3% | |
Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (202.12M) | (119.76M) | (9.06M) | (66.97M) | (74.62M) |
| Depreciation & Amortization | 11.26M | 11.87M | 9.65M | 7.54M | 5.52M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 23.13M | 20.44M | 18.37M | 29.44M | 14.29M |
| Change in Working Capital | 17.57M | (6.13M) | 53.32M | 1.39M | (28.33M) |
| Accounts Receivables | 12.7M | (45.84M) | 45.86M | 6.06M | (9.06M) |
| Inventory | (6.42M) | 55K | 230K | (2.19M) | (7.91M) |
| Accounts Payables | 7.13M | (10.86M) | 1.28M | (1.53M) | (280K) |
| Other Working Capital | 4.17M | 50.51M | 5.95M | (948K) | (11.08M) |
| Other Non-Cash Items | 6.33M | 6.63M | (150.48M) | (39.78M) | 2.1M |
| Operating Cash Flow | (143.83M) | (86.96M) | (78.21M) | (68.37M) | (81.04M) |
| Capital Expenditures | (6.2M) | (3.62M) | (1.76M) | (3.71M) | (1.91M) |
| Acquisitions (Net) | 0 | 0 | 64K | 0 | 11K |
| Purchases of Investments | (231.21M) | (120.6M) | (239.68M) | (77.18M) | (208.34M) |
| Sales of Investments | 200.8M | 194.94M | 161.3M | 190.03M | 96.14M |
| Other Investing Activities | 0 | 0 | 0 | 40.16M | 0 |
| Investing Cash Flow | (36.61M) | 70.72M | (80.08M) | 149.3M | (114.1M) |
| Debt Repayment | 0 | 0 | (157K) | 0 | 0 |
| Common Stock Issued | 117.82M | 1.09M | 1.17M | 3.44M | 129K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.96M | 574K | 149.35M | 960K | 69.39M |
| Financing Cash Flow | 122.78M | 1.66M | 150.36M | 960K | 69.51M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (57.66M) | (14.59M) | (7.93M) | 81.88M | (125.62M) |
| Free Cash Flow | (150.03M) | (90.58M) | (79.97M) | (72.08M) | (82.95M) |
MacroGenics, Inc.
NASDAQ:MGNX
Intrinsic Alpha fair value
Locked
Current Price
$1.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.